Frontiers | Incorporating Phase 0 Microdosing as a Powerful Tool Into a New Vision of Drug Development

Incorporating Phase 0 Microdosing as a Powerful Tool Into a New Vision of Drug Development

2,001
Total downloads
7,464
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 25 Jul 2024

When to consider intra-target microdosing: physiologically based pharmacokinetic modeling approach to quantitatively identify key factors for observing target engagement

Yasunori Aoki
Malcom Rowland
Yuichi Sugiyama

When to consider intra-target microdosing: physiologically based pharmacokinetic modeling approach to quantitatively identify key factors for observing target engagement

doi 10.3389/fphar.2024.1366160

813 views

EDITORIAL

Published on 16 Jul 2024

Editorial: Incorporating Phase 0 microdosing as a powerful tool into a new vision of drug development

H. Markus Weiss
Yuichi Sugiyama
Esther van Duijn

doi 10.3389/fphar.2024.1455643

542 views

METHODS

Published on 12 Apr 2024

Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment

Kenneth R. Gundle
Karthik Rajasekaran
Jeffrey Houlton
Gary B. Deutsch
Thomas J. Ow
Robert G. Maki
John Pang
Cherie-Ann O. Nathan
Daniel Clayburgh
24 more
Richard A. Klinghoffer

Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment

doi 10.3389/fphar.2024.1367581

1,636 views
1 citation

MINI REVIEW

Published on 18 Mar 2024

The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future

A. F. Roffel
E.-J. van Hoogdalem

The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future

doi 10.3389/fphar.2024.1369079

1,234 views

ORIGINAL RESEARCH

Published on 07 Mar 2024

Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model

Udomsak Udomnilobol
Wilasinee Dunkoksung
Watchara Sakares
Suree Jianmongkol
Thomayant Prueksaritanont

Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model

doi 10.3389/fphar.2024.1356273

1,095 views

Share on

Frontiers in Pharmacology

Frontiers in Pharmacology

Translational Pharmacology

Impact

7,464Topic views
4,756Article views
2,001Article downloads